Literature DB >> 10208302

Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.

R Bigoni1, S Giuliani, G Calo', A Rizzi, R Guerrini, S Salvadori, D Regoli, C A Maggi.   

Abstract

Nociceptin (NC), a series of NC fragments, naloxone as well as the pseudopeptide [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2 ([F/G]NC(1-13)NH2) were used to characterize NC receptors in peripheral isolated organs and in vivo. Experiments on isolated organs were performed in the mouse (mVD) and rat (rVD) vas deferens (noradrenergic nerve terminals), in the guinea pig ileum (gpI; cholinergic nerves) and in the renal pelvis (gpRP; sensory nerves), and, in vivo, by measuring the blood pressure (BP) and heart rate (HR) in anaesthetised rats. NC, NCNH2 and NC(1-13)NH2 acted as full agonists with similar affinities, while shorter fragments (e.g. NC(1-12)NH2, NC(1-9)NH2, NC(1-5)NH2) were much weaker or inactive. The inhibitory effects of NC were not modified by naloxone. [F/G]NC(1-13)NH2 acted as an antagonist with similar pA2-values (6.75 mVD, 6.83 rVD, 7.26 gpI) in the three species. In addition, it blocked NC actions in the rat in vivo. Linear Schild plots with slopes near to unity indicated that [F/G]NC(1-13)NH2 is a competitive antagonist, specific for NC receptors both in vitro (since it was inactive on opioid receptors) and in vivo (since it was inactive against carbachol). [F/G]NC(1-13)NH2 showed a residual agonistic activity in vitro (alpha = 0.2-0.3 in the rVD and gpI) and especially in vivo (alpha = 0.4 BP, 0.2 HR). These pharmacological data indicate that NC and related peptides exert their inhibitory effects in peripheral organs of various species by activating the same receptor type. Moreover, [F/G]NC(1-13)NH2 appears to be a useful tool for receptor characterization and classification.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208302     DOI: 10.1007/pl00005338

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle.

Authors:  M Ho; A D Corbett; A T McKnight
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain.

Authors:  R Bertorelli; L Corradini; K Rafiq; J Tupper; G Calò; E Ongini
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Nociceptin, Phe(1)psi-nociceptin(1 - 13), nocistatin and prepronociceptin(154 - 181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro.

Authors:  M Connor; C W Vaughan; E A Jennings; R G Allen; M J Christie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

5.  Inhibitory effect of nociceptin on [3H]-5-HT release from rat cerebral cortex slices.

Authors:  A Siniscalchi; D Rodi; L Beani; C Bianchi
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.

Authors:  S Molinari; V Camarda; A Rizzi; G Marzola; S Salvadori; E Marzola; P Molinari; J McDonald; M C Ko; D G Lambert; G Calo'; R Guerrini
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

7.  Stimulation of sensory neuropeptide release by nociceptin/orphanin FQ leads to hyperaemia in acutely inflamed rat knees.

Authors:  Chunfen Zhang; Jason J McDougall
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

8.  Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Authors:  M Marti; F Mela; M Budri; M Volta; D Malfacini; S Molinari; N T Zaveri; S Ronzoni; P Petrillo; G Calò; M Morari
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

9.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.